A phase I dose-escalation study for SYD985 (NCT02277717) in several HER2-expressing cancers determined the RP2D at 1.2 mg/kg and the most common TRAEs included fatigue and dry eye with reasonable anti-tumor activity across HER2-positive and HER2-low tumors. This evidence concerns the gene ERBB2 and dry eye syndrome.